IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY

MLA

Carella, A. M., et al. Improved Survival in Patients >= 60 with First Relapsed/Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine Vs Placebo Plus Cytarabine: Results from the Phase 3 Valor Study. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..95436718c33baecefa62295b904e5a96&authtype=sso&custid=ns315887. Accessed 18 Dec. 2024.

APA

Carella, A.-M., Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Norbert Vey, Strickland, S. A., Schiller, G. J., Jabbour, E., Erba, H. P., Pigneux, A., Horst, H.-A., Recher, C., Klimek, V. M., Cortes, J., Roboz, G. J., Craig, A. R., Fox, J. A., … Stuart, R. K. (n.d.). Improved Survival in Patients >= 60 with First Relapsed/Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine Vs Placebo Plus Cytarabine: Results from the Phase 3 Valor Study.

Chicago

Carella, A. -M, F. Ravandi, E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, Norbert Vey, et al. 2024. “Improved Survival in Patients >= 60 with First Relapsed/Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine Vs Placebo Plus Cytarabine: Results from the Phase 3 Valor Study.” Accessed December 18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..95436718c33baecefa62295b904e5a96&authtype=sso&custid=ns315887.